Our results support that the average modified Magee score, PR, Ki‐67, LN, and LVI status may be helpful in predicting patients with a higher risk of recurrence, and should be considered when risk stratifying breast cancer patients for systemic chemotherapy. The gene discussed is MKI67; the disease is breast cancer.